Radioligand Therapy Market Size, Share & Trends Analysis Report By Isotope (Lutetium-177 (Lu-177), Actinium-225 (Ac-225), Iodine-131 (I-131), Other Isotopes), By Target (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor), By Indication (Prostate Cancer, Neuroendocrine Tumours (NETs), Others), By End-User (Hospitals, Ambulatory Surgical Centers, Cancer Treatment Centers, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Global Radioligand Therapy Market Size

The global radioligand therapy market size was valued at USD 8.37 billion in 2024 and is projected to reach from USD 9.31 billion in 2025 to USD 17.09 billion by 2033, growing at a CAGR of 7.89% during the forecast period (2025-2033).

The radioligand therapy market is driven by the increasing prevalence of hard-to-treat cancers, such as neuroendocrine tumors and metastatic prostate cancer, where conventional therapies have limited success. Advancements in radiopharmaceuticals, including isotopes like Lutetium-177 (Lu-177) and Actinium-225 (Ac-225), are enhancing the precision of cancer treatment while minimizing damage to healthy tissues.

Key players such as Novartis (with Pluvicto), Bayer (with Xofigo), and Fusion Pharma are expanding their portfolios, bringing innovative radioligand therapies to market. Ongoing clinical trials, such as those combining Lu-177 with immune checkpoint inhibitors, are also exploring new therapeutic avenues to enhance efficacy, driving the market forward.

Moreover, rising government investments in cancer research and favorable regulatory approvals are supporting the rapid adoption of radioligand therapies worldwide. The increasing number of clinical collaborations and partnerships among biotech companies, such as Telix Pharmaceuticals and POINT Biopharma, is further accelerating the development of novel therapies, expanding the potential of radioligand treatments across multiple cancer types.

Radioligand Therapy Market Trends

Expansion to Treat Multiple Cancer Types

Radioligand therapy (RLT), originally developed for neuroendocrine tumors and prostate cancer, is increasingly gaining traction for its potential to treat a wider array of malignancies. Researchers are actively investigating the efficacy of RLT in treating various cancers, including lung, breast, and colon cancers, signaling a transformative shift in its therapeutic landscape. This expansion not only broadens the applicability of RLT but also unlocks substantial market opportunities.

• For instance, clinical trials such as NCT04104928 are evaluating the use of 177Lu-DOTATATE in non-small cell lung cancer (NSCLC). At the same time, other ongoing studies are focused on its effectiveness for HER2-positive breast cancer and colon cancer. These investigations could pave the way for RLT to be utilized across a spectrum of solid tumors, significantly enhancing its market potential and establishing it as a versatile treatment option in oncology.

As these trials progress and demonstrate positive outcomes, the adoption of radioligand therapy is expected to expand, benefiting both patients and the healthcare industry.

Radioligand Therapy Market Growth Factors

Surge in Cancer Cases Worldwide

The growing global burden of cancer is a major driver for the adoption of advanced treatments like radioligand therapy (RLT). As cancer cases continue to rise, particularly for prostate and neuroendocrine tumors, RLT is emerging as a crucial therapy due to its precision in targeting cancer cells while minimizing damage to healthy tissues. This makes it an attractive alternative when conventional treatments like chemotherapy or surgery are less effective.

• According to the American Cancer Society, the global cancer burden is projected to rise dramatically by 2040, with an estimated 27.5 million new cancer cases and 16.3 million cancer-related deaths expected worldwide. Cancers such as prostate and neuroendocrine tumors are expected to be major contributors to this increase.

In response, radioligand therapy (RLT) has emerged as an advanced, targeted treatment option. Compared to traditional therapies, RLT's ability to precisely target tumor cells while minimizing side effects has fueled its growing adoption, particularly for patients where conventional treatments are less effective.

Advancements in Nuclear Medicine and Imaging

The growth of the global radioligand therapy (RLT) market is significantly driven by advancements in nuclear medicine and imaging technologies. RLT relies on the precise delivery of radioisotopes that are conjugated to cancer-targeting molecules, enabling more effective treatments. Innovations in this field have facilitated enhanced targeting and treatment accuracy, particularly with therapies like Lutetium-177 (Lu-177).

• For instance, the FDA has approved Lutathera (Lu-177-DOTATATE) for neuroendocrine tumors and Pluvicto (Lu-177-PSMA-617) for metastatic prostate cancer, both showcasing the therapeutic potential of Lu-177. These advancements are attributed to improved nuclear imaging techniques, which enable clinicians to accurately visualize and localize tumors, ensuring that radioligand therapies are administered precisely where they are needed. As a result, patients experience better outcomes, including higher response rates and reduced side effects.

The continuous evolution of imaging modalities, coupled with the development of novel radioisotope therapies, will further propel the adoption of RLT, broadening its applications in oncology and driving market growth.

Restraining Factors

Limited Availability of Radioisotopes

Radioligand therapy relies on the availability of specific radioisotopes, such as Lutetium-177 and Actinium-225, which are crucial for targeting cancer cells. However, the production of these isotopes is limited to a few specialized facilities around the world, creating supply chain challenges. This limited supply can affect the availability of RLT and delay treatment for patients.

• For example, lutetium-177, a key isotope in radioligand therapy, is produced by a limited number of nuclear reactors worldwide. Major suppliers, like the Institute for Radioelements in Belgium, face potential disruptions due to reactor maintenance or delays, leading to shortages. This impacts the availability of treatments such as Lutathera for neuroendocrine tumors, creating a significant barrier to expanding RLT access globally.

Market Opportunities

Adoption of Combination Therapies

The adoption of combination therapies in radioligand therapy (RLT) is emerging as a promising strategy to enhance treatment outcomes. By integrating RLT with other modalities such as chemotherapy, immunotherapy, or targeted therapies, researchers aim to overcome resistance to single therapies and improve overall patient survival rates. This trend is gaining traction as clinical evidence supports the potential for synergy between RLT and other treatments.

A notable example is an ongoing clinical trial investigating the combination of 177Lu-PSMA-617 with Atezolizumab, a PD-L1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial seeks to evaluate the safety and anti-tumor efficacy of this combination, hypothesizing that blocking the PD-L1 pathway with Atezolizumab can enhance the immune system’s response initiated by RLT.

By improving tumor control through immune modulation and targeted radiotherapy, this approach is expected to provide a synergistic effect, offering better outcomes for patients. The success of such combination therapies could significantly expand the therapeutic potential of RLT, opening new avenues for cancer treatment and market growth.

Regional Insights

North America: Dominant region with 48.17% market share

North America held the largest share of the radioligand therapy market, driven by its advanced healthcare infrastructure, high levels of investment in cancer research, and early adoption of cutting-edge technologies. The presence of major pharmaceutical companies and research institutions, along with supportive regulatory frameworks and a high prevalence of cancer cases, further bolsters the market in the region.

Asia-Pacific: Rapid growth in China, Japan, and India

The Asia Pacific region is projected to witness the fastest CAGR in the radioligand therapy market, driven by increasing investments in healthcare infrastructure, rising cancer incidence, and growing awareness of advanced treatment options. Expanding access to cutting-edge therapies, supportive government initiatives, and increasing clinical research activities across countries like China, Japan, and India further fuel the region's rapid market growth.

Countries Insights

• U. S. – The U.S. is a leading market for radioligand therapy, driven by its advanced healthcare infrastructure, high investment in cancer research, and early adoption of cutting-edge technologies. The presence of major pharmaceutical companies and research institutions, such as the Memorial Sloan Kettering Cancer Center and Mayo Clinic, supports extensive clinical trials and the development of new therapies. The U.S. market is characterized by high patient access to radioligand treatments such as Lutathera for neuroendocrine tumors and PSMA-targeted therapies for prostate cancer. Regulatory support from organizations such as the FDA also accelerates the introduction of innovative therapies.

• Germany – Germany has a prominent position in the market within Europe, attributed to its strong emphasis on innovative healthcare solutions and research. The country boasts a high standard of medical facilities and advanced infrastructure that supports the administration of complex treatments. Favorable regulatory conditions, such as streamlined approval processes for novel therapies and significant government investments in healthcare research and development, further boost the growth of this market segment. Moreover, Germany's active participation in clinical trials and its role as a major player in European health initiatives drive the adoption of radioligand therapies.

• UK - The United Kingdom has a growing market supported by a well-established National Health Service (NHS) and cutting-edge research facilities. Institutions like The Royal Marsden NHS Foundation Trust and Institute of Cancer Research are at the forefront of implementing and researching radioligand therapies, such as Lutathera and 177Lu-PSMA. The UK's focus on personalized medicine and precision oncology aligns with the increasing adoption of radioligand therapy, driven by advancements in clinical trials and supportive regulatory frameworks.

• France - In France, the market is expanding due to the country’s advanced healthcare infrastructure and strong focus on oncology research. France’s leading cancer centers and academic institutions drive the adoption of new therapies, including radioligand treatments. Supportive regulatory frameworks and government initiatives aimed at enhancing cancer care further contribute to market growth. Moreover, the collaboration between French research institutes and pharmaceutical companies facilitates the development and implementation of radioligand therapies in clinical settings.

• Japan - Japan has a growing market, supported by its advanced medical technology and high cancer incidence rates. The country’s focus on precision medicine and investment in cancer research drive the adoption of radioligand therapies. Japan’s well-established healthcare system and regulatory support for innovative treatments contribute to market growth. Moreover, the presence of leading pharmaceutical companies and research institutions helps accelerate the development and availability of radioligand therapies.
• China - The China radioligand therapy market is expanding rapidly due to increasing cancer incidence and growing healthcare investments. China’s large population and rising awareness of advanced cancer treatments drive demand for innovative therapies. The country’s focus on improving healthcare infrastructure and supporting clinical research accelerates the adoption of radioligand therapies. Moreover, partnerships between Chinese pharmaceutical companies and international research organizations enhance the development and availability of these treatments.

• India - India is witnessing growth in the market, driven by a high burden of cancer and improving healthcare infrastructure. The country’s increasing focus on oncology research and development, along with rising patient awareness, supports the adoption of radioligand therapies. India’s growing network of specialized cancer treatment centers and government initiatives aimed at enhancing cancer care contribute to market expansion. Additionally, collaborations between local and global pharmaceutical companies facilitate the introduction of new therapies.

Radioligand Therapy Market Segmentation Analysis

By Isotope

The market is segmented into lutetium-177 (Lu-177), actinium-225 (Ac-225), and other isotopes. The lutetium-177 (Lu-177) segment dominates the global market due to its proven effectiveness in treating various cancers, particularly prostate and neuroendocrine tumors. Lu-177's favorable characteristics, such as its optimal half-life and ability to deliver targeted radiation to cancer cells while sparing healthy tissue, make it a preferred choice for radioligand therapies. Moreover, the success of treatments like Novartis' Lutetium-177 PSMA-617 (Pluvicto) has further reinforced the widespread adoption and growth of this segment.

By Target

The market is segmented into prostate-specific membrane antigen, ki 67 expression and grading, and cytochrome p450 17a1 inhibitor. The prostate-specific membrane antigen (PSMA) segment dominates the global market due to its highly targeted approach to treating prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). PSMA is overexpressed in most prostate cancer cells, making it an ideal target for radioligand therapies like Lutetium-177 PSMA-617. The proven efficacy of such treatments, along with growing approvals and clinical advancements, further strengthens the segment's leading position.

By Indication

The market is segmented into prostate cancer, neuroendocrine tumors (NETs), and others. The prostate cancer segment dominates the global market due to the high prevalence of the disease and the proven efficacy of radioligand treatments like Lutetium-177 PSMA in targeting prostate-specific membrane antigens. Moreover, increasing approvals of radioligand therapies, advancements in diagnostic technologies, and growing demand for more targeted and less invasive cancer treatments contribute to this segment's leading position in the market.

• For example, Novartis offers Lutetium-177 PSMA-617 (Pluvicto), approved by the FDA for treating metastatic castration-resistant prostate cancer (mCRPC), highlighting its effectiveness in targeted therapy.

By End-Users

The market is segmented into hospitals, ambulatory surgical centers, cancer treatment centers, and others. The hospital segment dominates the market with the largest share owing to its advanced infrastructure, access to specialized medical equipment, and the availability of trained healthcare professionals required for administering complex treatments such as radioligand therapy. Moreover, hospitals are often the first point of care for cancer patients, making them central to the adoption of innovative therapies. Furthermore, the ability of hospitals to handle radioactive materials safely and provide continuous patient monitoring further strengthens their position in this market segment.

Company Market Share

Key players in the radioligand therapy market are pursuing strategic collaborations, acquisitions, and partnerships to enhance their product offerings and broaden their market reach.

Fusion Pharmaceuticals Inc.: An emerging provider in the market

Fusion Pharmaceuticals Inc. is focused on developing advanced radiopharmaceuticals for targeted cancer therapies. They are known for their work on innovative treatments that leverage radioligand technology to improve targeting and efficacy in cancer treatment.

Recent Developments:

• In June 2022, clinical-stage oncology company Fusion Pharmaceuticals Inc. announced updates on its Phase 1 clinical trial evaluating FPI-1434 as a monotherapy for the treatment of solid tumors expressing IGF-1R and on its Phase 1 clinical trial investigating FPI-1966 for the treatment of solid tumors expressing FGFR3.

Recent Developments

• May 2024- Novartis AG announced its agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts. Mariana Oncology specializes in developing innovative radioligand therapies (RLTs) aimed at addressing cancers with significant unmet patient needs.
• May 2024- Bayer AG announced the start of a Phase I first-in-human clinical study for 225Ac-PSMA-Trillium, a next-generation targeted alpha therapy. This investigational drug, labeled with actinium-225 and featuring a novel PSMA-targeting molecule with a customized albumin-binding moiety, aims to enhance therapeutic efficacy while minimizing side effects in normal organs such as salivary glands.

Analyst Opinion

As per our analyst, the radioligand therapy market is expanding rapidly due to advances in targeted cancer treatments, increasing cancer incidence, and the development of new therapies that offer more precise and effective treatment options with fewer side effects. This growth is further supported by the rising adoption of personalized medicine, improved diagnostic capabilities, and regulatory approvals and partnerships that accelerate the development and availability of new radioligand treatments.